Final results of first line treatment with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (L-OHP) in advanced colorectal cancer (ACC): A multicenter phase II study.

被引：0
|
作者：
Souglakos, J [1 ]
Kouroussis, C [1 ]
Ziras, N [1 ]
Malamos, N [1 ]
Potamianou, A [1 ]
Mavroudis, D [1 ]
Kakolyris, S [1 ]
Androulakis, N [1 ]
Vardakis, N [1 ]
Georgoulias, V [1 ]
机构：
[1] Greek Cooperat Grp GI Tumors, Heraklion, Greece
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
215P
引用
收藏
页码：49 / 49
页数：1
相关论文
共 50 条
  • [31] Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study
    Neri, B.
    Pantaleo, P.
    Giommoni, E.
    Grifoni, R.
    Paoletti, C.
    Rotella, V.
    Pantalone, D.
    Taddei, A.
    Mercatelli, A.
    Tonelli, P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (07) : 1043 - 1046
  • [32] A phase II experience with neoadjuvant irinotecan (CPT-II), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases
    Bathe, Oliver F.
    Ernst, Scott
    Sutherland, Francis R.
    Dixon, Elijah
    Butts, Charles
    Bigam, David
    Holland, David
    Porter, Geoffrey A.
    Koppel, Jennifer
    Dowden, Scot
    BMC CANCER, 2009, 9
  • [33] Combination of oxaliplatin (OXA) and 5-fluorouracil, leucovorin (5-FU/LV), as first line therapy, in elderly patients >70years, with metastatic colorectal cancer.
    Botto, HG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 298S - 298S
  • [34] PRELIMINARY PHASE II RESULTS OF OXALIPLATIN, 5-FU AND LEUCOVORIN IN ADVANCED BILIARY TRACT CANCER
    Lee, N.
    Lee, S.
    Kim, K.
    Won, J.
    Kim, H.
    Kim, S.
    Kim, C.
    Park, S.
    Hong, D.
    Moon, J.
    Kim, H.
    Bae, S.
    Lee, K.
    Park, S.
    Park, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 98 - 98
  • [35] Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer
    Ji, SH
    Park, YS
    Lee, J
    Lim, DH
    Park, BB
    Park, KW
    Kang, JH
    Lee, SH
    Park, JO
    Kim, K
    Kim, WS
    Jung, CW
    Im, YH
    Kang, WK
    Park, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (04) : 214 - 217
  • [36] A Phase II Study of 5-Fluorouracil/Leucovorin in Combination with Paclitaxel and Oxaliplatin as First-Line Treatment for Patients with Advanced Gastric Cancer
    Lin, Rong-Bo
    Fan, Nan-Feng
    Guo, Zeng-Qing
    Wang, Xiao-Jie
    Liu, Jie
    Chen, Ling
    JOURNAL OF CHEMOTHERAPY, 2008, 20 (06) : 744 - 748
  • [37] Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy
    Falcone, A
    Pfanner, E
    Brunetti, I
    Allegrini, G
    Lencioni, M
    Galli, C
    Masi, G
    Danesi, D
    Antonuzzo, A
    Del Tacca, M
    Conte, PF
    TUMORI, 1998, 84 (06) : 666 - 668
  • [38] Oxaliplatin (LOHP) and 5-fluorouracil (5-FU) synergism in advanced colorectal cancer patients (ACRC)
    Meyer, V
    Delva, R
    Gamelin, E
    Lamezec, B
    Maillart, P
    DanquechinDorval, E
    Lortholary, A
    BoisdronCelle, M
    Maigre, M
    Brienza, S
    Cvitkovic, E
    Larra, F
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 746 - 746
  • [39] Economical evaluation of raltitrexed versus fluorouracil plus leucovorin (5-FU + LV) for treatment of advanced colorectal cancer
    Vorobyov, P
    Sura, M
    Avxentieva, M
    Papsheva, V
    VALUE IN HEALTH, 2002, 5 (06) : 538 - 538
  • [40] CPT-11 and L-OHP combination versus alternated combination of LV5FU2+CPT-11/LV5FU2+L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results
    Becouam, Y
    Mousseau, M
    Gamelin, E
    Coudert, B
    Marceau-Suissa, J
    Bekradda, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
12345